FDA May Amend Anticaries Monograph To Allow Combo Antiplaque Products
This article was originally published in The Rose Sheet
Executive Summary
FDA may be amenable to an oral rinse product that crosses the anticaries and antiplaque/antigingivitis monographs if studies demonstrate safety and efficacy, agency officials told Warner-Lambert at an OTC "feedback" meeting in Rockville, Md. Oct. 8.
You may also be interested in...
W-L Listerine Anticaries Fluoride Rinse Altered Formula Proposed To FDA
Warner-Lambert has changed its proposed fluoride-containing oral anticaries/antiplaque/antigingivitis rinse to a .02% sodium fluoride formula to reflect results from recently conducted market research, W-L says in comments submitted to FDA May 15.
W-L Listerine Anticaries Fluoride Rinse Altered Formula Proposed To FDA
Warner-Lambert has changed its proposed fluoride-containing oral anticaries/antiplaque/antigingivitis rinse to a .02% sodium fluoride formula to reflect results from recently conducted market research, W-L says in comments submitted to FDA May 15.
W-L Listerine, Lubriderm Sales See Double-Digit Growth In 1999
Listerine mouthwash sales totaled $487 mil. in 1999, a 13% increase, Warner-Lambert announced Jan. 19. The oral care business represented approximately 16% of the company's consumer health care sales, which were up 10% to $3 bil. U.S. consumer health care sales rose 14% to $1.7 bil.